PD-1 / PD-L1
Os inibidores de PD-1/PD-L1 são inibidores de checkpoints imunológicos que bloqueiam a interação entre a proteína de morte celular programada 1 (PD-1) nas células T e seu ligante PD-L1 nas células cancerígenas. Essa interação normalmente suprime a resposta imunológica e permite que as células cancerígenas evitem a detecção imunológica. Ao inibir PD-1/PD-L1, esses inibidores aumentam a capacidade do sistema imunológico de reconhecer e destruir células cancerígenas, induzindo apoptose e regressão tumoral. Os inibidores de PD-1/PD-L1 são fundamentais na pesquisa em imunoterapia e no tratamento do câncer. Na CymitQuimica, oferecemos uma gama de inibidores de PD-1/PD-L1 de alta qualidade para apoiar sua pesquisa em imunooncologia, apoptose e terapia do câncer.
Se han encontrado 125 productos de "PD-1 / PD-L1"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Sugemalimab
CAS:<p>Sugemalimab: human anti-PD-L1 IgG4 mAb with anticancer properties for non-small cell lung cancer.</p>Forma y color:LiquidTagitanlimab
CAS:<p>Tagitanlimab (HBM-9167) is a humanized IgG1κ anti-PD-L1 antibody, potentially for recurrent/metastatic NPC.</p>Forma y color:LiquidCosibelimab
CAS:<p>Cosibelimab, a fully human monoclonal antibody, blocks PD-L1, enabling ADCC and CDC against cancer cells.</p>Forma y color:LiquidGeptanolimab
CAS:<p>Geptanolimab (CBT-501) is a humanized IgG4κ antibody against PD-1, blocking PD-L1/PD-L2 binding to reactivate T cell activity.</p>Pureza:95% - 95%Forma y color:LiquidTuvonralimab
CAS:<p>Tuvonralimab, a combo of anti-PD-1/IgG4 and anti-CTLA-4/IgG1 antibodies, blocks dual immune checkpoints.</p>Forma y color:LiquidVudalimab
CAS:<p>Vudalimab: humanized antibody, blocks PD-1 & CTLA-4, boosts selective T-cell tumor response.</p>Forma y color:LiquidToripalimab
CAS:<p>Toripalimab is a humanized anti-PD-1 monoclonal antibody used as an immune checkpoint inhibitor in research for advanced malignancies like nasopharyngeal carcinoma.</p>Pureza:95% - 95%Forma y color:LiquidPucotenlimab
CAS:<p>Pucotenlimab (HX008) is an anti-PD-1 mAb that blocks PD-1/PD-L1/2 interactions, restoring immune function against solid tumours.</p>Pureza:95%Forma y color:LiquidPD-1/PD-L1-IN-20
CAS:<p>PD-1/PD-L1-IN-20 is a small molecule inhibitor of PD-1/PD-L1 protein-protein interaction.</p>Fórmula:C30H26BrClN2O3Forma y color:SolidPeso molecular:577.9PD-1/PD-L1-IN-NP19
CAS:<p>PD-1/PD-L1-IN-NP19: a PD-1/PD-L1 inhibitor with 12.5 nM IC50, may boost antitumor immunity.</p>Fórmula:C33H31ClN2O4Pureza:98%Forma y color:SolidPeso molecular:555.06PD-1-IN-22
CAS:<p>PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor(IC50 of 92.3 nM).</p>Fórmula:C25H25N5O4Pureza:99.51%Forma y color:SolidPeso molecular:459.5ASC-69
CAS:<p>ASC-69 (APY69) is a promising potent inhibitor of the PD-1/PD-L1 signaling pathway, classified as a small-molecule compound [1].</p>Fórmula:C19H19N7Pureza:98%Forma y color:SolidPeso molecular:345.4PD-L1-IN-2
CAS:<p>PD-L1-IN-2, a Naamidine J derivative, serves as a promising antineoplastic immunomodulator by hindering PD-L1 activity.</p>Fórmula:C33H38N4O6Pureza:98%Forma y color:SolidPeso molecular:586.68PD-1/PD-L1-IN-33
CAS:<p>PD-1/PD-L1-IN-33 (Compound N11), a PD-1/PD-L1 inhibitor, effectively impedes the interaction between PD-1 and PD-L1 with an IC50 of 6.3 nM.</p>Fórmula:C26H27N5OPureza:98%Forma y color:SolidPeso molecular:425.53PD-1/PD-L1-IN-34
CAS:<p>PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) effectively inhibits the PD-1/PD-L1 interaction (IC 50 = 0.029 μM) and demonstrates selective binding affinity to PD-L1</p>Fórmula:C35H33ClN2O3Pureza:98%Forma y color:SolidPeso molecular:565.1PD-1/PD-L1-IN-26
CAS:<p>PD-1/PD-L1-IN-26 is a strong inhibitor with IC50 of 0.0380 μM that may boost immune response in cancer by aiding CD4+ T cell entry to tumors.</p>Fórmula:C43H52N4O8Pureza:98%Forma y color:SolidPeso molecular:752.89PD-1/PD-L1-IN-27
CAS:<p>PD-1/PD-L1-IN-27: potent anti-cancer, IC50 134nM, minimal T cell harm, boosts CD8+ T cells, reduces fatigue.</p>Fórmula:C44H35NO6Pureza:98%Forma y color:SolidPeso molecular:673.75PD-L1-IN-3
CAS:<p>PD-L1-IN-3 is a PD-1/PD-L1 inhibitor for the study of tumors and immune diseases.</p>Fórmula:C19H15ClFN2OSPureza:99.47%Forma y color:SoildPeso molecular:373.85PD-1-IN-17
CAS:<p>PD-1-IN-17 is an inhibitor of programmed cell death-1 (PD-1). PD-1-IN-17 inhibits 92% splenocyte proliferation at 100 nM.</p>Fórmula:C13H22N6O7Pureza:99.6%Forma y color:SolidPeso molecular:374.35PD-1/PD-L1-IN-55
CAS:<p>PD-1/PD-L1-IN-55 (compound D6) is a potent PD-1/PD-L1 inhibitor with an IC50 of 4.8 nM. It enhances IFN-γ secretion and decreases the proportion of late apoptosis due to PD-L1.</p>Fórmula:C25H23ClN2O3Forma y color:SolidPeso molecular:434.92PD-L1-IN-7
CAS:<p>PD-L1-IN-7 (compound CB31) serves as a PD-L1 inhibitor, effectuating PD-L1 internalization and retention within cells. It restrains the PD-1/PD-L1 interaction (IC 50: 0.2 nM), alters glycosylation patterns, and facilitates PD-L1 degradation. Additionally, PD-L1-IN-7 enhances T cell infiltration, boosts T cell function, and augments the capacity to destroy tumor cells.</p>Fórmula:C46H50N6O7Forma y color:SolidPeso molecular:798.93PD-1/PD-L1-IN-53
CAS:<p>PD-1/PD-L1-IN-53 (compound B3) serves as an inhibitor targeting both the PD-1/PD-L1 and VISTA signaling pathways. It is utilized in cancer research.</p>Fórmula:C31H37N3O4Forma y color:SolidPeso molecular:515.64PD-L1/VISTA-IN-1
CAS:<p>PD-L1/VISTA-IN-1 (Compound P17) is an orally active dual inhibitor targeting PD-L1 and VISTA. It effectively hinders the PD-1/PD-L1 interaction (IC50: 0.1492 μM) and the VISTA pathway (KD: 0.2723 μM), leading to the reactivation of T cells. Additionally, PD-L1/VISTA-IN-1 exhibits antitumor activity.</p>Fórmula:C22H24N4O4Forma y color:SolidPeso molecular:408.45Enpp-1-IN-25
CAS:<p>Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and exhibits low oral bioavailability. By inhibiting cGAMP degradation, it effectively activates the intracellular STING pathway. Enpp-1-IN-25 can enhance immune cell infiltration and type I interferon response in the tumor microenvironment, thereby increasing the antitumor efficacy of anti-PD-L1 antibodies. It is applicable for research in cancer immunotherapy.</p>Fórmula:C15H21N5O4SForma y color:SolidPeso molecular:367.423INCB086550
CAS:<p>INCB086550 (PD-1/PD-L1-IN-8) (example 24) is a PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM.</p>Fórmula:C41H39N7O4Pureza:98.49%Forma y color:SolidPeso molecular:693.79
